Long-Term Outcomes of Scleroderma Renal Crisis PDF Print E-mail
Wednesday, 17 March 2010 13:59
Virginia D. Steen, MD, and Thomas A. Medsger Jr., MD
Published: October 17th, 2000

Background: Although scleroderma renal crisis, a complication of systemic sclerosis, can be treated with angiotensin-converting enzyme (ACE) inhibitors, its long-term outcomes are not known.

Objective: To determine outcomes, natural history, and risk factors in patients with systemic sclerosis and scleroderma renal crisis.

Design: Prospective observational cohort study.

Setting: University program specializing in scleroderma.

Patients: 145 patients with scleroderma renal crisis who received ACE inhibitors and 662 patients with scleroderma who did not have renal crisis.

Measurements: Among patients with renal crisis, the four outcomes studied were no dialysis, temporary dialysis, permanent dialysis, and early death. Demographic, clinical, and laboratory data were compared to identify risk factors for specific outcomes. Follow-up was 5 to 10 years.

Results: 61% of patients with renal crisis had good outcomes (55 received no dialysis, and 34 received temporary dialysis); only 4 of these (4%) progressed to chronic renal failure and permanent dialysis. More than half of the patients who initially required dialysis could discontinue it 3 to 18 months later. Survival of patients in the good outcome group was similar to that of patients with diffuse scleroderma who did not have renal crisis. Some patients (39%) had bad outcomes (permanent dialysis or early death). Conclusions: Renal crisis can be effectively managed when hypertension is aggressively controlled with ACE inhibitors. Patients should continue taking ACE inhibitors even after beginning dialysis in hopes of discontinuing dialysis.

Scleroderma renal crisis (1) is defined as the new onset of severe hypertension associated with a rapid increase in serum creatinine concentration, microangiopathic hemolytic anemia, or both. Outcomes of this disorder, a once-fatal complication of scleroderma, have dramatically improved with the use of angiotensin-converting enzyme (ACE) inhibitors (1). We examined short- and long-term outcomes
of renal crisis in patients taking these medications...

To continue reading the full article, please login in and download from the link provided below.

 
More articles :

» 5 Things to Know About Raynaud’s

Having a chronic condition like Raynaud’s requires vigilance. Here are five things that you should know about your condition from rheumatologists who treat it.Stay warm. Wear gloves and mittens and heavy socks whenever you expect to be in a cold...

» Greater Global Cooperation and Collaboration in Scleroderma Research Required

Greater global cooperation and collaboration among Scleroderma researchers and clinicians would be all that is required to fuel a drive toward important discoveries and optimize outcomes for patients with this chronic, progressive, and often...

» Immunosuppressive Medications During Pregnancy and Lactation In Women with Autoimmune Diseases

Amy B Elliott & Eliza F Chakravarty10.2217/WHE.10.24 © 2010 Future Medicine LtdWomen's Health (2010) 6(3), 431–442Most autoimmune diseases predominantly affect females. Many of these diseases occur in women who have the potential to become...

» Dr. Dinesh Khanna Named, "Doctor Of The Year"

The Scleroderma Foundation named Dinesh Khanna, M.D., M.Sc., its 2011 Doctor of the Year during this year's National Patient Education Conference held last month in San Francisco. The award recognizes a skilled physician or researcher for his or her...

» Pulmonary Arterial Hypertension And Scleroderma

is a disease that affects the skin and internal organs. The literal meaning of the word is "hard skin"; people with Scleroderma experience a hardening and tightening of their skin. The inflammation and scarring associated with Scleroderma can cause...

» HSCT Benefits In Early Diffuse Cutaneous Systemic Sclerosis

Initial results from an international, investigator-initiated, open label phase 3 trial, presented at EULAR 2012, indicate that haematopoietic stem cell transplantation (HSCT) results in better long-term survival than conventional treatment for...